Related Experiment Videos
[Sulodexide treatment in retinal vein obstructions]
Oftalmologia (Bucharest, Romania : 1990)
|October 1, 1996
Summary
Early treatment of retinal vein occlusion (RVO) with sulodexid, a thrombolytic agent, improves visual acuity. Prompt intervention within 48 to 72 hours is crucial for effective outcomes in RVO patients.
Area of Science:
- Ophthalmology
- Vascular Medicine
- Pharmacology
Background:
- Retinal vein occlusion (RVO) is a common posterior pole vascular disorder.
- Current RVO treatments often result in persistent visual acuity reduction.
- Visual acuity serves as the primary measure of treatment efficacy.
Purpose of the Study:
- To evaluate the efficacy of sulodexid in treating retinal vein occlusion.
- To determine the optimal timing for sulodexid intervention in RVO cases.
Main Methods:
- A study group received sulodexid, a drug with thrombolytic and fibrinolytic properties.
- Laser photocoagulation was administered adjunctively when necessary.
- Patient outcomes were assessed based on visual acuity.
Main Results:
- Sulodexid treatment demonstrated significant efficacy in improving visual acuity.
- The positive effects were most pronounced in patients treated early, within 48 to 72 hours of symptom onset.
- Delayed treatment showed less favorable visual outcomes.
Conclusions:
- Early intervention with sulodexid is critical for successful RVO management.
- Sulodexid, combined with laser photocoagulation when indicated, offers a promising therapeutic approach.
- Prompt treatment within 48-72 hours maximizes visual recovery in RVO patients.